629 Shares in argenx SE (NASDAQ:ARGX) Acquired by Brucke Financial Inc.

Brucke Financial Inc. purchased a new position in argenx SE (NASDAQ:ARGX - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 629 shares of the company's stock, valued at approximately $412,000.

Other institutional investors also recently added to or reduced their stakes in the company. GeoWealth Management LLC grew its position in shares of argenx by 56.3% in the 4th quarter. GeoWealth Management LLC now owns 50 shares of the company's stock worth $31,000 after buying an additional 18 shares during the last quarter. Steward Partners Investment Advisory LLC increased its holdings in shares of argenx by 5.6% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 380 shares of the company's stock valued at $234,000 after purchasing an additional 20 shares in the last quarter. SG Americas Securities LLC increased its holdings in shares of argenx by 6.2% during the 4th quarter. SG Americas Securities LLC now owns 358 shares of the company's stock valued at $220,000 after purchasing an additional 21 shares in the last quarter. Farther Finance Advisors LLC increased its holdings in shares of argenx by 38.2% during the 4th quarter. Farther Finance Advisors LLC now owns 76 shares of the company's stock valued at $47,000 after purchasing an additional 21 shares in the last quarter. Finally, Dynasty Wealth Management LLC increased its stake in shares of argenx by 3.4% during the fourth quarter. Dynasty Wealth Management LLC now owns 677 shares of the company's stock worth $416,000 after purchasing an additional 22 shares in the last quarter. Hedge funds and other institutional investors own 60.32% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the stock. Wedbush reissued an "outperform" rating and issued a $715.00 price objective on shares of argenx in a report on Friday, April 11th. Oppenheimer raised their price objective on shares of argenx from $704.00 to $708.00 and gave the company an "outperform" rating in a research note on Friday, May 9th. Robert W. Baird upgraded shares of argenx from a "neutral" rating to an "outperform" rating and set a $680.00 price target for the company in a research note on Tuesday, May 13th. Guggenheim decreased their target price on argenx from $1,100.00 to $1,065.00 and set a "buy" rating for the company in a research report on Friday, May 9th. Finally, Wells Fargo & Company boosted their price target on argenx from $723.00 to $741.00 and gave the company an "overweight" rating in a research report on Friday, February 28th. One analyst has rated the stock with a hold rating, nineteen have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $709.18.

argenx Price Performance

ARGX traded up $4.71 during mid-day trading on Thursday, hitting $580.95. The stock had a trading volume of 171,708 shares, compared to its average volume of 323,585. The stock's fifty day simple moving average is $587.69 and its 200-day simple moving average is $612.60. argenx SE has a 1-year low of $359.37 and a 1-year high of $678.21. The firm has a market capitalization of $35.47 billion, a price-to-earnings ratio of -660.17 and a beta of 0.57.

argenx (NASDAQ:ARGX - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.32 by $0.26. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The firm had revenue of $1.35 billion for the quarter, compared to analyst estimates of $748.34 million. As a group, research analysts expect that argenx SE will post 3.13 earnings per share for the current fiscal year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.